Serum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy

Clin Endocrinol (Oxf). 1990 Sep;33(3):317-21. doi: 10.1111/j.1365-2265.1990.tb00496.x.

Abstract

To study the activation of T lymphocytes in hyperthyroid Graves' disease, the serum concentrations of soluble interleukin 2 receptors (sIL2R) were determined during active thyrotoxicosis and following the return to a euthyroid state with carbimazole therapy. Serum sIL2R was measured by an enzyme linked immunoassay. The mean +/- SD serum sIL2R concentration during untreated hyperthyroidism was elevated as compared with controls (919.1 +/- 523.4 vs 374.2 +/- 189.4 U/ml, P less than 0.005). However, after carbimazole therapy the serum sIL2R in euthyroid patients fell to 377.9 +/- 90.3 U/ml, which did not differ from healthy controls. Serum sIL2R correlated significantly with the serum free T3 only during hyperthyroidism (r = 0.678, P less than 0.01). Our study suggests that in vivo measurement of serum sIL2R released from activated T lymphocytes is a useful immunological indicator of disease activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Carbimazole / therapeutic use*
  • Female
  • Graves Disease / blood*
  • Graves Disease / drug therapy
  • Humans
  • Lymphocyte Activation / drug effects
  • Male
  • Receptors, Interleukin-2 / analysis*
  • T-Lymphocytes / drug effects
  • Triiodothyronine / blood

Substances

  • Receptors, Interleukin-2
  • Triiodothyronine
  • Carbimazole